Clinical Trials

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today…
Read More...

Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major bleeding compared with…
Read More...

Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for cancer, and Molecular Templates, Inc., a privately held biopharmaceutical…
Read More...

Alkermes plc announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms…
Read More...

Ferring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research collaboration aimed at developing a mucoadhesive rectal delivery system to…
Read More...

Biocept, Inc., a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients,…
Read More...

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, and Definiens, the leader in Tissue Phenomics® solutions from biomarker discovery to meaningful…
Read More...

NuvOx Pharma announces that the first patients have been dosed in a Phase Ib/II clinical trial for NVX-208, an oxygen therapeutic being developed for acute ischemic stroke. The trial is…
Read More...

Concert Pharmaceuticals, Inc. announced that the results from the Company’s Phase 1 single and multiple ascending dose trial evaluating CTP-543 in healthy volunteers were presented in a…
Read More...

Integral Molecular and Integrated BioTherapeutics have teamed up in the fight against the global health crises posed by Ebola and Zika viruses, signing a collaborative vaccine discovery…
Read More...

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137,…
Read More...

Ligand Pharmaceuticals announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the…
Read More...

Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank announced a collaboration to develop FIN-403, an orally administered microbial…
Read More...

Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), today announced that it has entered into a collaboration with Frenova Renal…
Read More...

Amphastar Pharmaceuticals Inc said on Tuesday that the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose…
Read More...

Valeant Pharmaceuticals International, Inc. and EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing products for treating…
Read More...

ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a…
Read More...

CanniMed Therapeutics Inc. and CTT Pharmaceutical Holdings Inc.have entered into a definitive contractual relationship for the licensing of CTT’s Orally Dissolvable Thin Film (ODF)…
Read More...

Immune Pharmaceuticals Inc., will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that it will be launching REMAIN™, an international…
Read More...

Otsuka Pharmaceutical Co., Ltd. and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for REXULTI (brexpiprazole) for the treatment of schizophrenia in adults.…
Read More...